Navigating the Future
The regulatory revolution in gene therapy
Wei Xia ANG, Senior Regulatory Compliance Lead, Cytiva
The Asia-Pacific (APAC) region is rapidly advancing in cell and gene therapies (CGTs), with regulation at the core of its progress. While inspired by US and EU frameworks, APAC emphasizes localised innovation, cross-border collaboration, and harmonisation. Continued regulatory evolution and regional cooperation will be key to unlocking APAC’s full potential.
The cell and gene therapies (CGTs) landscape is evolving rapidly, with transformative potential to potentially cure rare diseases, cancers, and genetic disorders that were once deemed untreatable. As scientific advancements accelerate, the regulatory environment is hurrying to keep pace. While regions like the US and Europe have pioneered expedited approval frameworks, AsiaPacific (APAC) is quickly emerging as a critical hub for CGT development and commercialization. But navigating this future requires more than policy mimicry — it calls for regulatory innovation tailored to local realities. This includes not only aligning with global standards but also developing scalable models suited to regional economic and infrastructural diversity.
Global playbook, local game: Translating international standards into the APAC landscape
To expedite patient access to CGTs, regulators in the US and EU have introduced programmes like Fast Track, Breakthrough Therapy, Regenerative Medicine Advanced Therapy (RMAT), and Priority Medicines (PRIME), a scheme run by the European Medicines Agency (EMA) to enhance support for the development of medicines that target an unmet medical need. These programs foster early and frequent communication between sponsors and regulators, encouraging streamlined clinical development and faster approvals. They also provide greater predictability for developers, which is critical when navigating high-risk, capital-intensive projects like CGTs.
APAC regulators are following suit. Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) introduced the Sakigake designation and conditional/ time-limited approvals. Singapore’s Health Science Authority (HSA) offers pre-submission meetings and abbreviated reviews, while South Korea’s Ministry of Food and Drug Safety (MFDS) has launched fast-track designations like GIFT (Global Innovative Products on Fast Track). These frameworks reflect a growing recognition that innovation must be met with agility. This shift has also opened doors for smaller biotech firms in the region to compete in the global innovation race.
Cross-border initiatives like Project Orbis (led by the US FDA for oncology products), the ACCESS Consortium (involving Singapore, Australia, Canada, Switzerland and the UK), and the ASEAN Joint Assessment Procedure (JAP) promote parallel reviews and shared regulatory decisions. These collaborative mechanisms reduce redundancy, align technical standards, and support smaller regulatory agencies in building capacity. They represent a new era of information sharing across borders.
Yet, while regulatory convergence is accelerating, hurdles remain.
Manufacturing Challenges: Bridging the Compliance Gap
Advanced manufacturing standards, especially the use of single-use technologies, have become central to CGT production. These systems offer flexibility, reduce cross-contamination risk, and eliminate the need for complex cleaning validation associated with stainless-steel setups.
However, widespread adoption in APAC is hindered by high capital costs, legacy infrastructure, and logistical issues tied to the importation of disposable components. Cost-sensitive markets, lacking government incentives or access to private investment, often struggle to transition to globally accepted practices.
Further complicating matters are Chemistry, Manufacturing, and Controls (CMC) requirements, which are more complex in decentralised manufacturing models often used for personalized CGTs. Demonstrating consistency across sites, ensuring raw material quality from diverse sources, and navigating customs and trade delays create operational strain.
Additionally, regulatory fragmentation leads to inconsistent requirements for validation, analytical testing, and documentation. A harmonised regulatory checklist across APAC could significantly streamline these efforts and remove inefficiencies.
Shifting Sands: Navigating APAC’s Regulatory Diversity
APAC is not a monolith. Countries are progressing at varying speeds with different levels of regulatory maturity. Japan, South Korea, and Singapore have clear CGT frameworks and defined approval pathways. Others reference international standards (ICH, PIC/S, WHO) or piggyback on decisions made by stringent regulatory authorities (SRAs).
While such practices allow markets to gain experience and mitigate risk, they also create inconsistencies. Different regulators interpret Good Manufacturing Practice (GMP) principles differently, even within PIC/S members.
Pharmacopeial differences add another layer of complexity. While some countries accept global standards like USP or EP, others maintain national pharmacopeias or require localized validation of methods, forcing companies to manage multiple specifications for the same product.
Despite these challenges, hope lies in ongoing regulatory collaboration. The ASEAN JAP allows for joint submission and assessment across member states, reducing the need for market-by-market reviews. ACCESS Consortium members are increasingly aligning technical review standards. If fully implemented, these frameworks could set the stage for a more cohesive APAC regulatory environment. More importantly, they signal APAC’s readiness to play a formative role in shaping the global regulatory future for CGTs.
APAC on the Move: Embracing Innovation in Regulation
Beyond regulatory approvals, innovation in product assessment and validation is also changing. The increasing complexity of CGTs demands analytical sophistication. Traditional single-analyte testing is no longer sufficient. Regulators are encouraging the adoption of multi-attribute and high-throughput analytical platforms that provide a deeper understanding of critical quality attributes (CQAs).
Manufacturers are also shifting toward Quality by Design (QbD) approaches, which use process analytical technology (PAT) and design of experiments (DoE) to define and control critical process parameters (CPPs). This proactive strategy ensures product quality and robustness from development through commercial manufacturing.
Regulators are responding by adopting more flexible, risk-based approaches. Phase-appropriate validation, for instance, allows for broader acceptance criteria in early clinical trials and ramps up validation rigor closer to commercial approval. This stepwise model enables innovation without compromising patient safety.
Such evolution in regulatory thinking is particularly relevant for therapies with short shelf lives or those tailored to individual patients — areas where traditional drug approval models fall short. As CGTs increasingly move toward personalized applications, regulatory agility will be a defining success factor.
Enabling Readiness: Partnership and Technical Excellence
To navigate this evolving landscape, drug developers are increasingly turning to technology providers and solution partners for support.
In addition, organisations like the Parenteral Drug Association (PDA) and the International Society for Pharmaceutical Engineering (ISPE) serve as important conveners, bringing together regulators, manufacturers, and technology experts to share insights and align on best practices. These forums foster learning and help build common ground on technical and regulatory challenges.
By contributing technical knowledge and creating platforms for exchange, solution providers and conveners can support a more harmonized regulatory landscape — ultimately helping to advance patient access to innovative therapies.
Looking Ahead: Unlocking APAC’s Cell and Gene Therapy Potential
Ultimately, regulatory evolution is not just a technical challenge — it’s a strategic imperative. APAC’s potential to lead in CGTs hinges on cohesive government policy, sustained public-private collaboration, and a long-term vision for regional integration.
Governments must continue to invest in biomanufacturing infrastructure and provide Research and Development (R&D) funding to local biotech ecosystems. Incentives that attract venture capital and private equity — along with targeted tax or subsidy programmes — can stimulate early-stage innovation and enable global competitiveness.
Talent is another cornerstone. Manufacturing CGTs is highly labor-intensive, requiring skilled professionals in aseptic technique, cell handling, and process control. Policymakers should support education pipelines and create incentives to attract international expertise. Public-private partnerships with academic institutions could serve as a key enabler of this talent development.
By providing clear, actionable guidance, facilitating early engagement, and promoting transparency, regulatory agencies can help developers design smarter trials and navigate market entry more efficiently.
Industry, for its part, must step up as a collaborative partner. Drug developers should proactively share data, acknowledge knowledge gaps, and engage early and often with regulators. Sharing assessment outcomes across jurisdictions can support regulatory convergence and accelerate regional approvals.
As regulators grow more familiar with emerging technologies, their confidence and willingness to explore flexible, science based pathways will naturally increase. It’s a virtuous cycle: the more we learn, the faster we can act.
Conclusion: Path to CGT Leadership
The APAC region stands at a regulatory crossroads. The opportunity to become a global leader in CGT innovation is real but realizing it will require more than infrastructure or policy alignment. It will demand a fundamental shift in mindset: from reactive compliance to proactive collaboration.
By embracing regulatory innovation, encouraging regional collaboration, and investing in technical excellence, APAC can chart a path where patients benefit from timely access to life-changing therapies, and the region emerges not just as a participant — but a leader — in the global CGT revolution.
Author Bio
Wei Xia ANG holds a Ph.D. in Biological Sciences from National University of Singapore (NUS). She is currently overseeing regulatory compliance at Cytiva and providing regulatory support to customers. A recognized expert in her field, she has been invited to speak at multiple international conferences. Her previous experience includes serving as a medicinal products regulator at the Health Sciences Authority (HSA) of Singapore, managing regulatory affairs and regulatory strategies at a biotechnology company, and conducting scientific research at the Agency for Science, Technology and Research (A*STAR) in Singapore.
